rivoceranib,camrelizumab
jiangsu hengrui pharmaceuticals,elevar therapeutics
['pivotal', 'camrelizumab', 'rivoceranib']
camrelizumab plus rivoceranib produced the longest overall survival seen to date in a frontline pivotal phase 3 study of advanced hepatocellular carcinoma. #esmo22
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.